A Study in Healthy People to Test Whether BI 764198 Influences the Amount of Metformin in the Body

NCT07368569 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-04-14

No results posted yet for this study

Summary

The main objective of this trial is to investigate the effect on the exposure of metformin in plasma when administered as an oral multiple dose together with multiple oral doses of BI 764198 (Test, T) as compared to when metformin is administered as an oral multiple dose alone (Reference, R).

Conditions

Healthy

Interventions

DRUG

Metformin hydrochloride

DRUG

BI 764198

Sponsors & Collaborators

Boehringer Ingelheim
lead INDUSTRY

Study Design

Allocation: RANDOMIZED
Purpose: TREATMENT
Masking: NONE
Model: CROSSOVER

Eligibility

Min Age: 18 Years
Max Age: 55 Years
Sex: ALL
Healthy Volunteers: Yes

Timeline & Regulatory

Start: 2026-02-06
Primary Completion: 2026-03-14
Completion: 2026-03-17

Countries

Germany

Study Locations

More Related Trials

Entities

Companies

Boehringer Ingelheim

Summary

Conditions

Interventions

Sponsors & Collaborators

Study Design

Eligibility

Timeline & Regulatory

Countries

Study Locations

Related Clinical Trials

A Study in Healthy Men to Test Whether BI 1815368 Influences the Amount of Metformin in the Body

Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects

Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers

12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

4 Weeks Treatment of Type II Diabetic Patients With BI 44847

More Related Trials

Entities